COVID-19 Trials


ACTIV-2: A Study for Outpatients With COVID-19, National Institute of Allergy and Infectious Diseases (NIAID)

PI – Dr. Francis Riedo

Goal: To study the safety and effectiveness of different drugs in treating COVID-19 in outpatients.

  • Phase III, randomized, blinded, placebo-controlled trial.
  • Subjects in the study will be treated with either a study drug or with placebo.
  • Multicenter trial with 2000 subject enrollment goal.

For more information: contact EvergreenHealth Research Services at 425.899.5385 or email EvergreenResearch@evergreenhealth.com


Adaptive COVID-19 Treatment Trial 4 (ACTT-4), NIH

PI – Dr. Diego Lopez de Castilla

Goal: To evaluate the clinical efficacy of baricitinib + remdesivir versus dexamethasone + remdesivir as assessed by the mechanical ventilation free survival by Day 29.

  • Phase III, randomized, double-blind, placebo-controlled trial.
  • Subjects will be assessed daily while hospitalized. If the subjects are discharged from the hospital, they will have a study visit at Days 15, 22, and 29.
  • Multicenter trial with 100 centers globally and 1500 subject enrollment goal.

For more information: contact EvergreenHealth Research Services at 425.899.5385 or email EvergreenResearch@evergreenhealth.com


Boca Biolistics

Protocol #: CRSPTL-00012
PI – Dr. Diego Lopez de Castilla

Goal: Procure plasma and/or serum and other sample types from up to approximately 5,000 study subjects diagnosed positive for acute or chronic tropical or infectious diseases to evaluate the performance of new investigational devices or therapeutics.

  • 5000 samples worldwide.
  • EvergreenHealth providing 200 patient samples to evaluate antibodies in COVID-19 +ve patients.

For more information: contact EvergreenHealth Research Services at 425.899.5385 or email EvergreenResearch@evergreenhealth.com